.Pharmacolibrary.Drugs.ATC.N.N03AG04 .Pharmacolibrary.Drugs.ATC.N.N03AG04| name: | Vigabatrin |
| ATC code: | N03AG04 | route: | oral |
| n-compartments | 1 |
Vigabatrin is an antiepileptic drug used as adjunctive therapy in the treatment of refractory complex partial seizures and as monotherapy for infantile spasms (West syndrome). It is an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), increasing GABA levels in the brain. Approved and in use today in several countries, though usually reserved for refractory cases due to the risk of irreversible visual field defects.
Healthy adult volunteers, single or repeated oral doses, both sexes, various studies.
Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590
Nøhr, MK, et al., & Nielsen, CU (2015). Is oral absorption of vigabatrin carrier-mediated?. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 69 10–18. DOI:10.1016/j.ejps.2014.12.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25562534
Yu, DK, et al., & Weir, SJ (1994). A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data. Biopharmaceutics & drug disposition 15(6) 473–484. DOI:10.1002/bdd.2510150605 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7993985